Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 5,301–5,400 of 15,747
Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials
Tiwade, P. B., Fung, V., VanKeulen‐Miller, R., Narasipura, E. A., Ma, Y., & Fenton, O. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00871 · Cited by 21
Al-Ayyadhi, N., Ramadan, M. M., Al-Tayar, E. B. A., Al‐Mathkoori, R., & Al-Awadhi, S. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s338520 · Cited by 19
“Although the efficacy and safety of COVID-19 vaccines reaches 95% for preventing COVID-19, some people remain hesitant about being vaccinated against it.(4) Reluctance to accept vaccination is not limited to COVID-19 vaccines.”
BackgroundXiangxun, C., Wu, Y., Dau, V. T., Nguyen, N., & Ta, H. T. (2023) · Biomaterials Science · doi:10.1039/d2bm01594c · Cited by 21
Darling, T. L., Harastani, H., Joshi, A., Bricker, T. L., Soudani, N., Seehra, K., Hassan, A. O., Diamond, M., & Boon, A. C. M. (2024) · Science Advances · doi:10.1126/sciadv.adp1290 · Cited by 25
Zhang, X., Zhang, J., Chen, S., He, Q., Bai, Y., Liu, J., Wang, Z., Liang, Z., Chen, L., Mao, Q., et al. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2326094 · Cited by 22
“Vaccines administered via intramuscular injection can effectively induce high levels of circulating antibodies, effector and memory B cells, and T cells, thereby reducing disease severity and mortality rates [5–7].”
Impact of COVID-19 in patients with lymphoid malignancies
Riches, J. C. (2021) · World Journal of Virology · doi:10.5501/wjv.v10.i3.97 · Cited by 16
Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China
Wang, G., Zhu, L., Zhu, Y., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1913964 · Cited by 17
COVID-19 vaccines: A race against time
Peiffer‐Smadja, N., Rozencwajg, S., Kherabi, Y., Yazdanpanah, Y., & Montravers, P. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100848 · Cited by 16
Godbout, A., Drolet, M., Mondor, M., Simard, M., Sauvageau, C., Serres, G. D., & Brisson, M. (2022) · BMC Medicine · doi:10.1186/s12916-022-02398-x · Cited by 18
“In December 2020, 1 year after the beginning of the pandemic, the first COVID-19 vaccine was shown to be safe and highly efficacious against the disease and its complications [10].”
BackgroundImmune Prophylaxis and Therapy for Human Cytomegalovirus Infection
Struble, E. B., Murata, H., Komatsu, T. E., & Scott, D. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168728 · Cited by 23
“The mRNA vaccines developed by Moderna and Pfizer-BioNTech against COVID-19 have unequivocally established the feasibility of this platform [83,84].”
BackgroundSalmanton‐García, J., Marchesi, F., Koehler, P. A., Weinbergerová, B., Čolović, N., Falces‐Romero, I., Buquicchio, C., Farina, F., Praet, J. T. V., Biernat, M., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106952 · Cited by 17
Badanta, B., García, M. A., Jiménez, Á. E., Lucchetti, G., & de Diego‐Cordero, R. (2023) · EXPLORE · doi:10.1016/j.explore.2023.02.005 · Cited by 19
Comparative characteristics of COVID-19 vaccines used for mass immunisation
Онищенко, Г. Г., Sizikova, T. E., Lebedev, V. N., & Borisevich, S. V. (2021) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2021-21-3-158-166 · Cited by 21
“В ходе финальной стадии исследований вакцины BNT162b2 оценка ее эффективности составила 95% [3].”
Bouwmans, P., Messchendorp, A. L., Imhof, C., Sanders, J., Hilbrands, L. B., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, R. M. A., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac249 · Cited by 20
Nonviral targeted mRNA delivery: principles, progresses, and challenges
He, X., Li, G., Huang, L., Shi, H., Zhong, S., Zhao, S., Jiao, X., Xin, J., Yin, X., Liu, S., et al. (2025) · MedComm · doi:10.1002/mco2.70035 · Cited by 28
Wang, X., Pahwa, A., Bausch-Jurken, M. T., Chitkara, A., Sharma, P., Malmenäs, M., Vats, S., Whitfield, M. G., Lai, K. Z. H., Dasari, P., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03117-7 · Cited by 18
Qassim, S. H., Hasan, M. R., Tang, P., Chemaitelly, H. S., Ayoub, H. H., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Rahim, H. F. A., Nasrallah, G. K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984784 · Cited by 20
“Nearly all vaccinated persons received their second vaccine dose per protocol (17, 18) within 30 days of first dose.”
BackgroundHeald, A. H., Rea, R. D., Horne, L., Metters, A., Steele, T., Leivesley, K., Whyte, M., Stedman, M., & Ollier, W. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14714 · Cited by 17
Reinfection of SARS-CoV-2 – analysis of 23 cases from the literature
Roberts, A. T., Piani, F., Longo, B., Andreini, R., & Meini, S. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1905174 · Cited by 17
Schumacher, F., Mrdenovic, N., Scheicht, D., Pons‐Kühnemann, J., Scheibelhut, C., & Strunk, J. (2022) · Rheumatology · doi:10.1093/rheumatology/keac036 · Cited by 15
Nurses’ mental health from early COVID‐19 pandemic to vaccination
Kim, S. C., Rankin, L., & Ferguson, J. (2021) · Journal of Nursing Scholarship · doi:10.1111/jnu.12760 · Cited by 20
Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice
Tian, S., Ji, K., Wang, M., Wang, F., Wang, H., Huang, W., Huang, Q., & Yan, J. (2021) · Cell Discovery · doi:10.1038/s41421-021-00331-9 · Cited by 16
A Route to Synthesize Ionizable Lipid ALC-0315, a Key Component of the mRNA Vaccine Lipid Matrix
Boldyrev, I. A., Shendrikov, V. P., Vostrova, A. G., & Vodovozova, E. L. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020061 · Cited by 19
Durability of immune responses to the BNT162b2 mRNA vaccine
(2021) · doi:10.1101/2021.09.30.462488 · Cited by 17
Ramphul, K., Ramphul, Y., Park, Y., Lohana, P. J. D., Dhillon, B. K., & Sombans, S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105065 · Cited by 20
Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens
Heidari, Z., Tajbakhsh, A., Hayat, S. M. G., Moattari, A., Razban, V., Berenjian, A., Savardashtaki, A., & Negahdaripour, M. (2021) · Recent Patents on Biotechnology · doi:10.2174/1872208315666210419103742 · Cited by 20
Iancovici, L., Khateeb, D. M., Harel, O., Peri, R., Slobodin, G., Hazan, Y., Melamed, D., Kessel, A., & Bar‐On, Y. (2021) · Rheumatology · doi:10.1093/rheumatology/keab879 · Cited by 20
Meggiolaro, A., Sane Schepisi, M., Farina, S., Castagna, C., Mammone, A., Siddu, A., Stefanelli, P., Boccia, S., & Rezza, G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2130773 · Cited by 17
Antisense oligonucleotide: A promising therapeutic option to beat COVID ‐19
Quéméner, A. M., & Galibert, M. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1703 · Cited by 20
“The mRNA vaccines manufactured by Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) encode the fulllength SARS-CoV-2 S glycoprotein stabilized in its prefusion conformation (Baden et al., 2021; Jackson et al., 2020; Polack et al., 2020).”
BackgroundSmith, L., Sim, J., Amlôt, R., Cutts, M., Dasch, H. K., Sevdalis, N., Rubin, G. J., & Sherman, S. M. (2021) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2021.110679 · Cited by 17
“[8 – 10] The cause of adverse effects from vaccination is not always clear.”
InfluentialCorrao, G., Franchi, M., Cereda, D., Bortolan, F., Zoli, A., Leoni, O., Borriello, C., Valle, G. P. D., Tirani, M., Pavesi, G., et al. (2022) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(21)00813-6 · Cited by 17
Mohamed, R., White, T. M., Lazarus, J. V., Salem, A. A., Kaki, R., Marrakchi, W., Kheir, S. G. M., Amer, I. F., Ahmed, F. M., Khayat, M. A., et al. (2022) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v23i1.1391 · Cited by 18
Prendecki, M. F., Thomson, T., Clarke, C., Martin, P., Gleeson, S., de Aguiar, R. C., Edwards, H., Mortimer, P. M., McIntyre, S., Lewis, S., et al. (2021) · medRxiv · doi:10.1101/2021.07.09.21260192 · Cited by 21
Khare, S., Niharika, N., Singh, A., Hussain, I., Singh, N. B., & Singh, S. C. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04181-3 · Cited by 16
“3 ml each) according to the following regimen: a single dose followed by a second dose 21 days later and showed up to 95% efficacy [7].”
MethodNucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity
(2021) · doi:10.1101/2021.04.26.441518 · Cited by 17
“Studies of the highly efficacious Pfizer/BioNTech and Moderna mRNA vaccines show a strong correlation between neutralizing antibodies (NAb) response and protection from disease (1, 2).”
BackgroundGuo, Z., Sörös, P., Zhang, Z., Yang, M., Liao, D., & Liu, C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.765106 · Cited by 21
“Although a number of vaccines have been proved to be effective (7, 8), evidence-based evaluations and interventions targeting mental health disorders are relatively scarce (9).”
BackgroundPlatelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID‐19 vaccine
Flego, D., Cesaroni, S., Romiti, G. F., Corica, B., Marrapodi, R., Scafa, N., Maiorca, F., Lombardi, L., Pallucci, D., Pulcinelli, F. M., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15648 · Cited by 18
Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms
Pineda-Peña, A.-C., Hasegawa, K., Pavot, V., Berry, C., Combadière, B., Cortés-Garcia, G., McDermott, A. B., & Sridhar, S. (2025) · npj Vaccines · doi:10.1038/s41541-025-01302-x · Cited by 25
Nakagami, H., Hayashi, H., Sun, J., Yanagida, Y., Otera, T., Nakagami, F., Hamaguchi, S., Yoshida, H., Okuno, H., Yoshida, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10091427 · Cited by 21
Bayesian spatio-temporal analysis of the COVID-19 pandemic in Catalonia
Satorra, P., & Tebé, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-53527-w · Cited by 21
Lam, M., Egail, M., Bedlow, A., et al. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.14673 · Cited by 17
Webster, E. R., Peck, N. E., Echeverri, J. D., Gholizadeh, S., Tang, W.-L., Woo, R. W. L., Sharma, A., Liu, W., Rae, C. S., Sallets, A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c05513 · Cited by 21
Bordi, L., Sberna, G., Piscioneri, C. N., Cocchiara, R. A., Miani, A., Grammatico, P., Mariani, B., & Parisi, G. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.05.061 · Cited by 17
Auroux, M., Laurent, B., Coste, B., Massy, E., Mercier, A., Durieu, I., Confavreux, C. B., Lega, J., Mainbourg, S., & Coury, F. (2022) · Joint Bone Spine · doi:10.1016/j.jbspin.2022.105380 · Cited by 18
Jiang, M., Väisänen, E., Kolehmainen, P., Huttunen, M., Ylä‐Herttuala, S., Meri, S., Österlund, P., & Julkunen, I. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.049 · Cited by 24
“This may be due to the overall composition of the vaccines including the lower amount of mRNA per dose in BNT1162b2 (30 lg) [22] than in mRNA-1273 vaccine (100 lg) [23].”
Predictors of COVID-19 Vaccination Likelihood Among Reproductive-Aged Women in the United States
Gutierrez, S., Logan, R. G., Marshall, C. J., Kerns, J., & Diamond‐Smith, N. (2022) · Public Health Reports · doi:10.1177/00333549221081123 · Cited by 18
Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
Alharbi, N. K., Al‐Tawfiq, J. A., Alwehaibe, A., Alenazi, M. W., Almasoud, A. S., Algaissi, A. A., Alhumaydhi, F. A., Hashem, A. M., Bosaeed, M., & Alsagaby, S. A. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s362848 · Cited by 20
“COVID-19 in adults.(9) Although reports of an allergic reaction (anaphylaxis) after receiving the first dose of the vaccine have emerged, the vaccine's adverse events were acceptable and similar to those following previously implemented vaccines.”
ResultNovel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
Voss, C. J. D., Marcellus, Li, S., Ateere, A., McShane, H., & Stylianou, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1540359 · Cited by 30
mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People
Garbuglia, A. R., Minosse, C., & Porto, P. D. (2022) · Viruses · doi:10.3390/v14040748 · Cited by 17
“The main adverse effects reported were fatigue, chills, muscle pain and fever [40,78].”
BackgroundAMDV Vaccine: Challenges and Perspectives
Markarian, N. M., & Abrahamyan, L. G. (2021) · Viruses · doi:10.3390/v13091833 · Cited by 18
“Both mRNA-1273 (Moderna) and BNT162b2 (Pfizer–BioNTech) rely on lipid-nanoparticle (LNP) encapsulated mRNA expressing the pre-fusion stabilized spike glycoprotein, which is translated upon entering the cells [147,148].”
BackgroundThe significance of advanced COVID-19 diagnostic testing in pandemic control measures
Kwok, H. F. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72837 · Cited by 22
“Although multiple phase III clinical trials have shown highly positive results on the effectiveness and safety of several vaccines [7-10] and therapeutic agents [11-15], vaccines and therapeutic agents are far from perfect with respect to preventing transmission or curing patients who developed severe disease.”
BackgroundmRNA Vaccines: Current Applications and Future Directions
Li, J., Liu, Y., Dai, J., Li, Y., Xiong, F., Xia, J., Jin, J., Wu, Y., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70434 · Cited by 40
Assessing the Optimality of a COVID Lockdown in the United States
Scherbina, A. D. (2021) · Economics of Disasters and Climate Change · doi:10.1007/s41885-021-00083-6 · Cited by 16
“Polack et al. (2020) establish that some protection is achieved already after the first Pfizer-BioNTech vaccine dose: The vaccine has an efficacy of 52% after the first dose, and of 95% after the second dose.”
BackgroundLin, H., Chen, C.-C., Chiao, D.-J., Chang, T.-Y., Chen, X.-A., Young, J., & Kuo, S.-C. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.020 · Cited by 18
Garcia-Cirera, S., Calvet, J., Berenguer, A., Pradenas, E., Marfil, S., Massanella, M., Mateu, L., Trinité, B., Llop-Vilaltella, M., Arévalo, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18996-x · Cited by 19
Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia
Alharbi, N. K., Al‐Tawfiq, J. A., Alghnam, S. A., Alwehaibe, A., Alasmari, A., Alsagaby, S. A., Alotaibi, F. M., Alsubaie, F., Alshomrani, M., Fl, F., et al. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.04.001 · Cited by 18
“In clinical trials, the efficacy rates, in preventing symptomatic SARS-CoV-2 infections, were 52% (95% CI: 30–86%) after one dose and 95% (95% CI: 90–98%) after two doses of BNT162b2 [8]; and 70% (95% CI: 55–81%) after two doses of the AZD1222 vaccine [9].”
Scialò, F., Vitale, M., Daniele, A., Nigro, E., Perrotta, F., Gelzo, M., Iadevaia, C., Cerqua, F. S., Costigliola, A., Allocca, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9060611 · Cited by 18
“These efforts have resulted in the development and production of different vaccines, some of which, such as Pfizer (BTN162b2) with an efficacy of 95% in preventing Covid-19 infection [62], Moderna with 90% mRNA 1273 and AstraZeneca with 70%, already being used to vaccinate millions of people.”
BackgroundZhang, P., Li, Y., Wang, H., Luo, L., Wang, P., Wang, H., Li, Q., Meng, Z., Yang, H., Liu, Y., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.877668 · Cited by 19
“According to clinical reports, this COVID-19 vaccination is very effective in reducing severe illness and deaths from COVID-19, and the vaccine has been shown to be safe with extremely low risks of side effects (15, 33, 34).”
MethodZecca, E., Rizzi, M., Tonello, S., Matino, E., Costanzo, M., Rizzi, E., Casciaro, G. F., Manfredi, G. F., Acquaviva, A., Gagliardi, I., et al. (2022) · Viruses · doi:10.3390/v14081766 · Cited by 20
Pegorari, M. S., Silva, C. D. F. R., de Araújo, F. C., da Silva, J. D. S., Ohara, D. G., Matos, A. P., Matos, A. P., & Pinto, A. C. P. N. (2021) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0195-2020 · Cited by 20
“00 [4-30] Social Isolation (LSNS-6) (n/%) Yes 20 (23.”
Nazaruk, P., Monticolo, M., Jędrzejczak, A. M., Krata, N., Moszczuk, B., Sańko-Resmer, J., Pilecki, T., Urbanowicz, A., Florczak, M., Pączek, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9121454 · Cited by 18
“Both vaccines are reportedly effective in preventing severe disease in more than 90% of the general population, across all age groups and in pre-specified subgroups at high risk of severe disease [2,3].”
BackgroundTracking SARS-CoV-2 variants by entire S-gene analysis using long-range RT-PCR and Sanger sequencing
Matsubara, M., Imaizumi, Y., Fujikawa, T., Ishige, T., Nishimura, M., Miyabe, A., Murata, S., Kawasaki, K., Taniguchi, T., Igari, H., et al. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.014 · Cited by 17
Ma, N., Xia, Z.-W., Zhang, Z., Nian, X., Li, X.-D., Gong, Z., Zhang, G., Yang, L., Zhou, R., Zhang, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2202278 · Cited by 20
“Among them, mRNA vaccine is a newly developed platform in recent years and has previously been used in the prevention of infectious diseases caused by rabies virus[14], human immunode fi ciency virus[15], respiratory syncytial virus[16], Zika virus [17], or SARS-CoV-2[18].”
Mori, M., Yokoyama, A., Shichida, A., Sasuga, K., Maekawa, T., & Moriyama, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-46823-4 · Cited by 28
“After the first and second doses in the BNT162b2 trial, axillary swelling was recorded as an unsolicited reaction only 25 .”
BackgroundWørzner, K., Schmidt, S., Zimmermann, J., Tami, A., Polacek, C., Fernandez-Antunez, C., Hartmann, K. T., Jensen, R. F., Hansen, J. S., Illigen, K. E. E., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105615 · Cited by 20
Tadic, S., & Martínez, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433185 · Cited by 23
Lataster, R. (2024) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13962 · Cited by 21
Ruiz‐Giardín, J. M., Rivilla, M., Plaza, N. M., Ortega, A. M., Rivas, L., Izquierdo-Martínez, A., Escriba, A., Martín, J. S., Bello, D. B., Madroñal, E., et al. (2022) · Viruses · doi:10.3390/v14102284 · Cited by 17
“Messenger RNA (mRNA) vaccines (BNT162b2 and mRNA-1273) were the first to demonstrate protection against severe cases [5,6].”
BackgroundThe importance of sustained compliance with physical distancing during COVID-19 vaccination rollout
Teslya, A., Rozhnova, G., Pham, T. M., van Wees, D. A., Nunner, H., Godijk, N. G., Bootsma, M., & Kretzschmar, M. (2022) · Communications Medicine · doi:10.1038/s43856-022-00207-3 · Cited by 17
Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures
Guo, W., Porter, L., Crozier, T. W. M., Coates, M. L., Jha, A., McKie, M. A., Nathan, J. A., Lehner, P. J., Greenwood, E. J. D., & McCaughan, F. M. (2022) · Life Science Alliance · doi:10.26508/lsa.202101116 · Cited by 20
“The recent success of the SARS-CoV-2 vaccine trials in protecting against COVID-19 disease has had a major impact on the pandemic (Polack et al, 2020; Baden et al, 2021; Voysey et al, 2021).”
Fröhlich, G., de Kraker, M. E. A., Abbas, M., et al. (2022) · Archive ouverte UNIGE (University of Geneva) · doi:10.5167/uzh-225142 · Cited by 17
Murano, K., Guo, Y., & Siomi, H. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210859 · Cited by 19
Switzer, B., Haanen, J. B. A. G., Lorigan, P. C., Puzanov, I. J., & Turajlic, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002835 · Cited by 17
Fidler, S. J., Fox, J. M., Tipoe, T., Longet, S., Tipton, T., Abeywickrema, M., Adele, S., Alagaratnam, J., Ali, M., Aley, P. K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac796 · Cited by 21
Veluswamy, P., Wacker, M., Stavridis, D., Reichel, T., Schmidt, H., Scherner, M. P., Wippermann, J., & Michels, G. (2021) · Viruses · doi:10.3390/v13071346 · Cited by 20
Schultz, M. D., Suschak, J. J., Botta, D., Silva-Sánchez, A., King, R. G., Detchemendy, T. W., Meshram, C. D., Foote, J. B., Zhou, F., Tipper, J. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2127292 · Cited by 17
Terpos, E., Trougakos, I. P., Karalis, V. D., Ntanasis‐Stathopoulos, I., Sklirou, A. D., Bagratuni, T., Papanagnou, E., Patseas, D., Gumeni, S., Malandrakis, P., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26248 · Cited by 17
“adenovirus vector (AstraZeneca-AZ) vaccines account for the majority of vaccinations following the encouraging clinical trial results.(1,2) Age, gender and comorbidities, such as hematologic malignancies, may have an impact on antibody response.”
BackgroundLuo, M., Zhou, R., Tang, B., Liu, H., Chen, B., Liu, N., Mo, Y., Zhang, P., Lee, Y. L., Ip, J. D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105354 · Cited by 18
Zou, Z., Fairley, C. K., Shen, M., Scott, N., Xu, X., Li, Z., Li, R., Zhuang, G., & Zhang, L. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.11.024 · Cited by 18
Harboe, Z. B., Hamm, S. R., Pérez‐Alós, L., Sivapalan, P., Priemé, H., Wilcke, T., Kjeldgaard, P., Shaker, S. B., Jordan, A. S., Møller, D. L., et al. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001268 · Cited by 20
Eifer, M., Pinian, H., Klang, E., Alhoubani, Y., Kanana, N., Tau, N., Davidson, T., Konen, E., Catalano, O. A., Eshet, Y., et al. (2022) · European Radiology · doi:10.1007/s00330-022-08725-3 · Cited by 17
“Unilateral lymphadenopathy is a known finding following COVID-19 mRNA vaccine [1, 2].”
BackgroundInfluentialSchäfer, A., Kovacs, M. S., Eder, A., Nigg, A. P., & Feuchtenberger, M. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06329-2 · Cited by 22
Lai, C., Kim, D.-K., Kang, S., Li, K., Cha, I., Sasaki, A., Porras, J., Xia, T., & Jung, J. U. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29183 · Cited by 19
“Although rare, there are reports of adverse effects of COVID ‐ 19 mRNA vaccines, such as acute myocardial infarction, Bell's palsy, cerebral venous sinus thrombosis, stroke, and thrombosis with thrombocytopenia syndrome, 6 amongst others.”
BackgroundLoosen, S. H., Bohlken, J., Weber, K., Konrad, M., Luedde, T., Roderburg, C., & Kostev, K. (2022) · Vaccines · doi:10.3390/vaccines10040566 · Cited by 16
Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis
Gushchin, V. А., Pochtovyi, A. A., Kustova, D. D., Ogarkova, D. A., Tarnovetskii, I. Y., Belyaeva, E. D., Divisenko, E. V., Vasilchenko, L. A., Shidlovskaya, E. V., Kuznetsova, N. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314670 · Cited by 17
COVID-19 vaccine induced Axillary and Pectoral Lymphadenopathy on PET scan
Singh, B., Kaur, P., Kumar, V., & Maroules, M. (2021) · Radiology Case Reports · doi:10.1016/j.radcr.2021.04.053 · Cited by 17
“Four re-lated serious adverse events reported among BNT162b2 recipients (shoulder injury related to vaccine administration, right axillary lymphadenopathy, paroxysmal ventricular arrhythmia, and right leg paresthesia) [1] .”
Attash, H. M., Al-Obaidy, L. M., & Al-Qazaz, H. (2022) · Vaccines · doi:10.3390/vaccines10020186 · Cited by 17
“, observed that the prevalence of symptoms was similar after first and second doses [18].”
BackgroundImplication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
Al‐Tawfiq, J. A., Koritala, T., Alhumaid, S., Barry, M. A., Alshukairi, A. N., Temsah, M.-H. A., Mutair, A. S. A., Rabaan, A. A., Tirupathi, R., & Gautret, P. (2022) · Infection · doi:10.1007/s15010-022-01759-1 · Cited by 17
“In a company-sponsored study, researchers tested 20 volunteers immunized with BNT162b2 from the original clinical trial [29] for neutralization.”
BackgroundBoedecker-Lips, S. C., Lautem, A., Runkel, S., Klimpke, P., Kraus, D., Keil, P., Holtz, S., Tomalla, V., Marczynski, P., Boedecker, C., et al. (2022) · Pathogens · doi:10.3390/pathogens11010067 · Cited by 19
Chen, X., Xu, Y., Xie, Y., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100758 · Cited by 17
Qin, S., Huang, H., Xiao, W., Chen, K., He, X., Tang, X., Huang, Z., Zhang, Y., Duan, X., Fan, N., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.010 · Cited by 16
Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination
Atoui, A., Jarrah, K., Mahmasani, L. A., Bou‐Fakhredin, R., & Taher, A. T. (2022) · Annals of Hematology · doi:10.1007/s00277-021-04743-1 · Cited by 18
“The Pfizer BioNTech vaccine was the first approved vaccine for the prevention of COVID-19 infection, with an efficacy reaching 95% and a favorable safety profile and no VTE cases reported [3].”
MethodAnalysis of Delayed Vaccination Regimens: A Mathematical Modeling Approach
González‐Parra, G. (2021) · Epidemiologia · doi:10.3390/epidemiologia2030021 · Cited by 16
Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M. G., Premji, Z., Issa, H. G., et al. (2022) · medRxiv · doi:10.1101/2022.10.02.22280610 · Cited by 16
Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
Wi, Y. M., Kim, S., & Peck, K. R. (2021) · Vaccines · doi:10.3390/vaccines9080931 · Cited by 16
“Although the incidence rates of AEs of the BNT162b2 and the AZD1222 vaccines were different in previous clinical studies, the method of monitoring AEs might have resulted in the differences [4,5].”
BackgroundResultInfluentialTakamatsu, A., Honda, H., Kojima, T., Murata, K., & Babcock, H. M. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.325 · Cited by 16
“After the prevaccination questionnaire survey period, all HCP received a double-sided, color leaflet in Japanese with information on the COVID-19 vaccine and answers to frequently asked questions, such as (1) an explanation of the mRNA vaccine, (2) current evidence of its safety, efficacy, and common adverse events, (…”
Method(2021) · doi:10.1101/2021.08.29.21262792 · Cited by 141
SARS-CoV-2 inflammation durably imprints memory CD4 T cells
Gray-Gaillard, S. L., Solis, S., Chen, H. M., Monteiro, C., Ciabattoni, G. O., Samanovic, M. I., Cornelius, A. R., Williams, T., Geesey, E., Rodriguez, M., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj8526 · Cited by 28
Kayabölen, A., Akcan, U., Özturan, D., Polat, H. Ü., Şahin, G. N., Degirmenci, N. P., Bayraktar-Odabas, C., Söyler, G., Sarayloo, E., Nurtop, E., et al. (2022) · Advanced Science · doi:10.1002/advs.202201294 · Cited by 18
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.